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Abstract Over the last 15 years, various oncology groups
throughout the world have used the PRETEXT system for
staging malignant primary liver tumours of childhood. This
paper, written by members of the radiology and surgery
committees of the International Childhood Liver Tumor
Strategy Group (SIOPEL), presents various clarifications
and revisions to the original PRETEXT system.
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Introduction
The PRETEXT system was designed by the International
Childhood Liver Tumor Strategy Group (SIOPEL) for
staging and risk stratification of liver tumours [1, 2].
PRETEXT is used to describe tumour extent before any
therapy, thus allowing more effective comparison between
studies conducted by different groups. The system has good
interobserver reproducibility [3] and good prognostic value
in children with hepatoblastoma [2–5], and is the basis of
risk stratification in current SIOPEL hepatoblastoma stud-
ies. Most other study groups now use the PRETEXTsystem
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Padua, Italyto describe imaging findings at diagnosis, even if this is not
their main staging system.
Certain limitations of the system have become obvious
over the last 15 years. In addition, there have been
significant advances in imaging during this period [6]. This
paper is the report of a working party that met in June 2005
to update the PRETEXT system.
PRETEXT staging is based on Couinaud’s system of
segmentation of the liver (Fig. 1)[ 7]. The liver segments
are grouped into four sections as follows: segments 2 and 3
(left lateral section), segments 4a and 4b (left medial
section), segments 5 and 8 (right anterior section) and
segments 6 and 7 (right posterior section). The term section
is used (where other authors use segment or sector) to avoid
terminological confusion.
In the original system, the caudate lobe (segment 1) was
ignored. The PRETEXT number was derived by subtract-
ing the highest number of contiguous liver sections that
Fig. 1 Schematic representations of the segmental anatomy of the
liver. a Frontal view of the liver. The numerals label Couinaud’s
segments 2t o8 . b The hepatic veins (black) and the intrahepatic
branches of the portal veins (grey) are shown. Segment 1 (equivalent to
the caudate lobe) is seen to lie between the portal vein and the inferior
vena cava. c Exploded frontal view of the segmental anatomy of the
liver. The umbilical portion of the left portal vein (LPV) separates the
left medial section from the left lateral section (LLS). Segment 1 is
obscured in this view. Note that the term “section” has been used in
preference to “segment” or “sector” (see text). d Transverse section of
the liver shows the planes of the major venous structures used to
determine the PRETEXT number. The hepatic (blue) and portal
(purple) veins define the sections of the liver (2–8). This schematic
diagram shows how the right hepatic (RHV) and middle hepatic
(MHV) veins indicate the borders of the right anterior section (RAS)
with the right posterior (RPS) and left medial (LMS) sections. Note that
the left portal vein (LPV) actually lies caudal to the confluence of the
hepatic veins and is not seen in the same transverse image. The left
hepatic vein (LHV) runs between segments 2 and 3 and is not used in
PRETEXT staging
Table 1 Definitions of PRETEXT number (see text for PRETEXT
number of tumours involving the caudate lobe)
PRETEXT number Definition
I One section is involved and three adjoining
sections are free
II One or two sections are involved,
but two adjoining sections are free
III Two or three sections are involved,
and no two adjoining sections are free
IV All four sections are involved
124 Pediatr Radiol (2007) 37:123–132were not involved by tumour from four [1]. This number is,
very roughly, an estimate of the difficulty of the expected
surgical procedure (Table 1). Pedunculated tumours are
considered to be confined to the liver and to occupy only
the section(s) from which they originate.
In addition to describing the intrahepatic extent of the
primary tumour(s), the PRETEXT system includes certain
other criteria. These assess involvement of the inferior vena
cava (IVC) or hepatic veins (designated V), involvement of
the portal veins (P), extrahepatic abdominal disease (E) and
distant metastases (M).
The purpose of the 2005 revision was to improve the
original definitions of the PRETEXT stages, to clarify the
criteria for “extrahepatic” disease, and to add new criteria
(Table 2). The term “extrahepatic” disease is confusing, and
these categories will in future be called “additional criteria”.
There is still much to be learned about prognostic factors in
the primary malignant liver tumours of childhood. An
important goal of these changes, therefore, is to improve
our ability to identify prognostic imaging findings, and
thereby refine risk stratification.
Although the PRETEXT system is principally used for
hepatoblastoma, the 2005 revision is intended to be
applicable to all primary malignant liver tumours of
childhood, including hepatocellular carcinoma and epitheli-
oid haemangioendothelioma. The original SIOPEL risk
stratification system for hepatoblastoma has already been
modified in the protocols for current SIOPEL studies
(Table 3). Firstly, tumour rupture or intraperitoneal haemor-
rhage at the time of diagnosis (H1, see below) is now a
defining criterion of high risk. Secondly, children with alpha-
fetoprotein levels of <100 μg/l are also considered to be high
risk. The 2005 revision involves no further change in the
SIOPEL risk stratification system for hepatoblastoma.
Table 2 2005 PRETEXT staging: additional criteria
Caudate lobe involvement C C1 Tumour involving the caudate lobe All C1 patients are at
least PRETEXT II C0 All other patients
Extrahepatic abdominal
disease
E E0 No evidence of tumour spread in the abdomen (except
Mo rN )
Add suffix “a” if ascites
is present, e.g., E0a
E1 Direct extension of tumour into adjacent organs or
diaphragm
E2 Peritoneal nodules
Tumour focality F F0 Patient with solitary tumour
F1 Patient with two or more discrete tumours
Tumour rupture or
intraperitoneal haemorrhage
H H1 Imaging and clinical findings of intraperitoneal
haemorrhage
H0 All other patients
Distant metastases M M0 No metastases Add suffix or suffixes to
indicate location (see text) M1 Any metastasis (except E and N)
Lymph node metastases N N0 No nodal metastases
N1 Abdominal lymph node metastases only
N2 Extra-abdominal lymph node metastases (with or without
abdominal lymph node metastases)
Portal vein involvement P P0 No involvement of the portal vein or its left or right
branches
See text for definition of
involvement. Add suffix “a”
if intravascular tumour is
present, e.g., P1a
P1 Involvement of either the left or the right branch of the
portal vein
P2 Involvement of the main portal vein
Involvement of the IVC and/
or hepatic veins
V V0 No involvement of the hepatic veins or inferior vena cava
(IVC)
See text for definition of
involvement. Add suffix “a” if
intravascular tumour is present,
e.g., V3a
V1 Involvement of one hepatic vein but not the IVC
V2 Involvement of two hepatic veins but not the IVC
V3 Involvement of all three hepatic veins and/or the IVC
Table 3 Risk stratification in hepatoblastoma for current SIOPEL
studies
High risk Standard risk
Patients with
any of the
following:
Serum alpha-fetoprotein
<100 μg/l
All other patients
PRETEXT IV
Additional PRETEXT
criteria:
E1, E1a, E2, E2a
H1
M1 (any site)
N1, N2
P2, P2a
V3, V3a
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The traditional approach to radiological segmentation of the
liver, based on the paths of the hepatic veins, is an
oversimplification. This is partly due to the variability of
hepatic venous anatomy [8–10]. The main problem,
however, is the imperfect correlation with segments defined
by the branching pattern of the portal veins [8, 11–13].
Although the plane of the right hepatic vein reliably
separates the right posterior and anterior sections [9], the
left hepatic vein runs to the left of the boundary between
the left lateral and medial sections, which is best defined by
the plane of the fissure of the ligamentum teres and the
umbilical portion of the left portal vein (Fig. 1)[ 14].
Fig. 2 PRETEXT I. a The left
lateral section (segments 2 and
3) is involved. b The right
posterior section (segments 6
and 7) is involved
Fig. 3 PRETEXT II. a Tumour involving only the right lobe of the
liver. b A transverse T1-weighted MR image of a child with
hepatoblastoma shows that the middle hepatic vein (arrow)i s
displaced but not involved by the tumour. This is the most common
type of PRETEXT II tumour. c Tumour involving only the left lobe of
the liver. d Tumour involving only the left medial section. e Tumour
involving only the right anterior section. f Multifocal tumours
involving only the left lateral and right posterior sections. g The
tumour is confined to the caudate lobe (PRETEXT II C1, see text;
RPV right portal vein)
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This group includes only a small proportion of primary
malignant liver tumours of childhood. From the definition
of the PRETEXT number, it can be seen that only tumours
localized to either the left lateral section or the right
posterior section qualify as PRETEXT I (Fig. 2).
PRETEXT II
Most PRETEXT II tumours are limited to either the right
lobe or the left lobe of the liver. Tumours of the left medial
or right anterior sections are also PRETEXT II. Multifocal
tumours involving only the left lateral and right posterior
sections are classified as PRETEXT II; this pattern is very
rare. Tumours limited to the caudate lobe were not
classifiable under the original PRETEXT system [1]. In
the 2005 PRETEXT system these tumours are classified as
PRETEXT II (but see also C, below). This is the only
change in the PRETEXT numbering system in this revision.
There is no change in numbering for tumours involving the
caudate lobe and any other part of the liver, which are
classified as PRETEXT II (if two or three contiguous
sections are free), III (if there are no two contiguous
sections free) or IV (if all four sections are involved)
(Fig. 3).
PRETEXT III
The unifocal tumours in this category spare only the left
lateral or right posterior section. These tumours are
relatively common. In children with hepatoblastoma, great
care must be taken to distinguish between invasion and
compression of the apparently uninvolved section of the
liver, because risk stratification (and/or the need for liver
transplantation) may depend on this point. Anterior central
liver tumours involve segment 4 and either or both of
segments 5 and 8. Although recent advances in surgical
Fig. 4 PRETEXT III. a Extensive tumour sparing only the left lateral
section. b Extensive tumour sparing only the right posterior section. c
Anterior central liver tumour involving the left medial and right
anterior sections. d Contrast-enhanced CT image shows a central liver
tumour lying between the left portal vein (white arrow) and the right
hepatic vein (black arrow). e Multifocal PRETEXT III tumour,
sparing the right anterior section. f Multifocal tumours sparing only
the left lateral and right anterior sections. g Multifocal tumours sparing
only the left medial and right posterior sections
Pediatr Radiol (2007) 37:123–132 127technique permit resection of these tumours without
trisectionectomy [15], classification as PRETEXT III
reflects the difficulty of these operations (Fig. 4).
Multifocal PRETEXT III tumours may also spare the
right anterior or left medial sections, or two non-contiguous
sections. These patterns are rare.
PRETEXT IV
PRETEXT IV tumours involve all sections of the liver.
These tumours are often multifocal. Alternatively, a very
large solitary tumour can involve all four sections
(Fig. 5).
C: caudate lobe tumours
The caudate lobe and caudate process (segment 1 or
segments 1 and 9, depending on the system of nomencla-
ture) can be resected with either the left or right lobe of the
liver [7]. For this reason, segment 1 was not considered in
the PRETEXT classification in the original system [2].
Modern surgical techniques have made resection of
segment 1 safer, but these operations remain difficult.
Involvement of the caudate lobe is, therefore, a potential
predictor of poor outcome. If any tumour is present in
segment 1 on imaging at diagnosis (Fig. 3g), the patient
will be coded as C1, irrespective of the PRETEXT group
(see above). All other patients should be coded as C0.
E: extrahepatic abdominal disease
The assessment of extrahepatic abdominal disease was one
of the most confusing aspects of the original PRETEXT
system, and clearly needed revision. Originally, there was a
requirement for all extrahepatic abdominal spread of
tumour (E+) to be proved by biopsy. Modern imaging
techniques are capable, in principle, of identifying extrahe-
patic abdominal tumour extension in many forms. The
frequency and significance of these imaging findings is
different for different tumour types, and not all patterns are
easily biopsied.
In hepatoblastoma, for example, direct extension of
tumour into other abdominal organs is unusual. Tumour
extension through the diaphragm (Fig. 6) is uncommon, but
can be shown quite convincingly by MRI or CT, and biopsy
proof may be impractical. In the 2005 revision, patients
with direct extension of tumour through the diaphragm or
into other organs can be coded as E1 without biopsy proof.
Pedunculated tumours are considered to be confined to
the sections from which they arise, and are not extrahepatic
disease.
Peritoneal tumour seeding was originally not included in
this category [2]. It probably indicates more advanced
abdominal disease than direct extension of the primary
tumour. Imaging techniques, especially ultrasonography,
can often show even small peritoneal nodules clearly, and
the differential diagnosis is very limited. In the 2005
revision, peritoneal nodules will be assumed to be metas-
Fig. 5 PRETEXT IV. a Multi-
focal PRETEXT IV tumours
involve all four sections.
b Contrast-enhanced CT image
of a patient with PRETEXT IV
F1 (see text) hepatoblastoma.
c Unifocal PRETEXT IV
tumours often have a diffuse
growth pattern. d Contrast-en-
hanced CT image of a patient
with diffuse PRETEXT IV
hepatoblastoma
128 Pediatr Radiol (2007) 37:123–132tases, and will be coded as E2. All other patients should be
coded as E0.
Ascites is an unusual finding at presentation in hepato-
blastoma, but is more common in hepatocellular carcinoma,
where it may be an independent predictor of poor
prognosis. For this reason, patients with ascites will be
coded as E0a, E1a or E2a as appropriate.
Abdominal lymph node metastases, which were previ-
ously recorded as E+, are now coded as N (see below).
F: tumour focality
In SIOPEL 1, multifocal tumours were identified at the time
of diagnosis in 18% of the patients with hepatoblastoma
where this information was available [4]. Univariate
analysis showed that the 5-year event-free survival was
significantly worse for patients with multifocal tumour
(40%) than for those with unifocal tumour (72%) [4]. The
independent significance of this finding is unclear, as there
is clearly an association between multifocality and ad-
vanced PRETEXT number. The German Society of
Pediatric Oncology and Hematology reported slightly
different results [16]. In its HB89 study, 21% of patients
had multiple well-defined tumours, and these children had a
similar disease-free survival (DFS; 87%) to those with a
single tumour (86%). However, in 20% of children the
tumour exhibited a diffuse growth pattern (Fig. 5), and
these had a significantly worse DFS (21%) [16]. Unfortu-
nately, a diffuse growth pattern is difficult to define, and
despite the promise that this finding shows as a potential
risk factor, it was decided not to incorporate it in the 2005
PRETEXT revision.
Patients with one hepatic tumour should be coded as F0.
All those with more than one tumour nodule (Figs. 3, 4 and
5), regardless of nodule size or PRETEXT stage, should be
coded as F1.
H: tumour rupture or intraperitoneal haemorrhage
It is not uncommon for hepatoblastoma and hepatocellular
carcinoma to present with tumour rupture [17, 18].
Originally, these patients were not automatically included
as high risk in SIOPEL studies, because of the requirement
that extrahepatic disease (E) be proved by biopsy.
Although the data to prove this are not currently available,
it seems intuitively likely that tumour rupture (usually
manifesting as intraperitoneal haemorrhage) is a risk
factor, and these patients should be coded as H1.
Laparotomy or aspiration of peritoneal blood is not
necessary for diagnostic purposes if characteristic imaging
and clinical findings (such as hypotension and low
haematocrit or haemoglobin level) are present. The
presence of peritoneal fluid on imaging alone does not
imply tumour rupture (but see E above).
Since the opening of the SIOPEL 4 study in September
2004, tumour rupture has become a defining feature of
high-risk hepatoblastoma in SIOPEL studies. Patients with
no evidence of tumour rupture or haemorrhage, and those
with only subcapsular or biopsy-related intraperitoneal
bleeding, are coded as H0.
Fig. 6 Extrahepatic abdominal
tumour extension. This compos-
ite of contrast-enhanced CT
images in a patient with hepato-
blastoma shows growth of the
primary tumour through the di-
aphragm into the thorax (E1).
The 2005 PRETEXT system no
longer requires biopsy proof for
this form of tumour spread
Pediatr Radiol (2007) 37:123–132 129M: distant metastases
Patients with distant metastases at diagnosis are coded as
M1. In hepatoblastoma, these metastases are predominantly
found in the lungs. Although the best imaging modality for
the identification of lung metastases is currently CT, the
defining characteristics of lung metastases in this context
have not been specifically studied. It is believed, however,
that factors favouring a diagnosis of metastasis include
multiple lesions, a rounded, well-defined contour and a
subpleural location. In most parts of the world, a single
rounded lung lesion with a diameter of >5 mm in a child
with a primary liver tumour is very likely to be a metastasis.
Patients with these findings on chest CT scans should be
classified as M1. Biopsy is not required for staging
purposes, because it is uncommon for other lesions to
mimic metastases in this clinical context. The protocols of
the SIOPEL studies recommend central radiological review
if there is any doubt about the presence of lung metastases.
Other metastases are infrequently found at diagnosis in
hepatoblastoma, but are more common in hepatocellular
carcinoma. The imaging findings of brain metastases are
usually characteristic, and biopsy is not required.
Bone scintigraphy is recommended for staging in
children with hepatocellular carcinoma, but not hepatoblas-
toma. Abnormal calcium metabolism is common in
children with hepatoblastoma, and may cause abnormal
uptake on bone scintigraphy, especially in the ribs [19],
whereas bone metastases are rare [20]. Biopsy proof is
therefore mandatory for suspected bone metastases in
hepatoblastoma, unless the findings of cross-sectional
imaging are characteristic and the patient is already in the
high-risk category for some other reason, such as the
presence of lung metastases.
Bone marrow biopsy is not recommended in children
with hepatoblastoma, because bone marrow spread is rare
[20]. It is not known whether metastases at different sites
have different prognostic implications. For statistical
purposes, it is therefore recommended that one or more
suffixes be added to M1 to indicate the major sites of
metastasis: pulmonary (p), skeletal (s), central nervous
system (c), bone marrow (m), and other sites (x). A child
with lung, brain, and adrenal metastases would therefore
be coded as M1cpx. Patients with no evidence of
haematogenous metastatic spread of tumour should be
coded as M0.
N: lymph node metastases
Because porta hepatis (and other abdominal) lymph node
metastases are quite unusual in hepatoblastoma, SIOPEL
trials have always required this form of tumour spread to be
proved by biopsy. In fact, benign enlargement of lymph
nodes is probably not uncommon, and the accuracy of
positron emission tomography is not known in this context.
Because biopsy of equivocal lymph nodes inevitably carries
some risk, the SIOPEL committee actively discourages this.
Biopsy may, however, be required if there is significant
nodal enlargement (for example short axis >15 mm) in a
child with no other criteria for high-risk hepatoblastoma.
Lymph node metastases are quite common in hepatocel-
lular carcinoma and fibrolamellar carcinoma, and biopsy
proof is not required if the imaging abnormality is
unequivocal. An arbitrary threshold short axis diameter of
15 mm is suggested for this purpose.
Children with no lymph node metastases by these
criteria are coded as N0, those with nodal metastases
limited to the abdomen (i.e. caudal to the diaphragm and
cranial to the inguinal ligament) as N1, and those with
extra-abdominal nodal metastases as N2.
P: portal vein involvement
Involvement of the main portal vein and/or both major
branches has been considered a risk factor in hepatoblas-
toma, because this has obvious implications for the
resectability of the tumour. It is also possible that portal
vein invasion detected by imaging is an independent risk
factor for tumour recurrence [21]. The original PRETEXT
criteria, however, did not specifically define the word
“involvement”.
It is well recognized that a tumour that abuts or displaces
a major portal venous branch at imaging performed at
diagnosis (Fig. 7) may shrink away from the vein following
preoperative chemotherapy. Imaging evidence of complete
obstruction or circumferential encasement (Fig. 7)i s
therefore required to qualify as portal vein involvement.
Failure to identify the portal vein or one of its major
branches in either its normal position or its expected
displaced location, on good quality images, is strong
evidence of obstruction. The other form of involvement,
portal vein invasion, is not uncommon, and is often best
detected by ultrasound (Fig. 7). Various US signs may be
present [22, 23], and analogous findings can be seen on CT
and MR imaging.
Patients with no imaging evidence of involvement of the
main portal vein, its bifurcation, or either of its main
branches will be coded as P0. Those who fulfil the original
PRETEXT definition of P+ (involvement of the main portal
vein, its bifurcation, or both of its main branches), as well
as those with “cavernous transformation” of the portal vein
will be coded as P2. P2, however, represents very advanced
disease. For this reason, the category P1 has been created
for patients with evidence of involvement of one major
130 Pediatr Radiol (2007) 37:123–132branch of the portal vein. In addition, the detection of portal
vein invasion should be marked by the suffix “a” (e.g.,
P2a).
V: involvement of the IVC and/or hepatic veins
The same definitions of involvement (venous obstruction,
encasement and/or invasion) used for the portal veins apply
to the hepatic veins (Fig. 7). A hepatic vein can be assumed
to be involved if it cannot be identified at all, and its
expected course runs through a large tumour mass. It is
important to look carefully for the hepatic veins, preferably
with ultrasonography as well as CT and/or MRI, as they
may be displaced from their expected position by the
tumour. Complete obstruction of the IVC can occur with
mass effect alone, without any tumour extension to the vein
itself. Inability to visualize the IVC, and the presence of an
enlarged azygos vein, are not, therefore, sufficient criteria
for involvement. Patients with no imaging evidence of
involvement of the hepatic veins or IVC will be coded as
V0.
As for the portal vein, the original classification of
involvement(V+)indicated averyadvancedlevelofdisease.
Intermediate categories have therefore been created. V1 and
V2 indicate involvement of one or two main hepatic veins
respectively. V3 indicates involvement of either the IVC or
all three of the hepatic veins. In addition, the detection of
hepatic vein or IVC invasion should be marked by the suffix
“a” (e.g., V2a). The presence of tumour in the right atrium
automatically makes a patient V3a.
SIOPEL risk stratification for patients
with hepatoblastoma
The SIOPEL risk stratification for children with hepato-
blastoma is essentially unchanged by this revision. Patients
Fig. 7 Involvement of the por-
tal and hepatic venous systems.
a When the tumour (grey)
approaches or abuts the vein
(black), there is no venous in-
volvement, even if the vein is
partly encased. b Complete ob-
struction or encasement of the
vein is one form of involvement.
Obstruction of the inferior vena
cava by extrinsic compression,
however, does not count as
involvement (see text). c Intra-
vascular tumour growth in the
portal and/or hepatic venous
systems is not uncommon in
children with hepatoblastoma or
hepatocellular carcinoma.
d Transverse ultrasound image
of the right lobe of the liver in a
patient with hepatoblastoma.
The tumour (white circles) has
grown into the right branch of
the portal vein (P1a), disrupting
the normal “white line” of the
vein wall (arrows)
Pediatr Radiol (2007) 37:123–132 131with any one or more of certain criteria (Table 3) are high
risk. All other SIOPEL patients are standard risk.
Presurgical re-evaluation
Although the timing of surgery will depend on the
treatment protocol and the patient’s response to therapy,
preoperative reimaging is almost always necessary. All of
the PRETEXT categories should be reassessed after
preoperative chemotherapy, as near as possible to the time
of surgery, and recorded as POSTEXT (post-treatment
extent of disease). Comparison of surgical findings with
POSTEXT will allow prospective assessment of the
accuracy of imaging techniques.
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